Artigo Acesso aberto Revisado por pares

PMU79 TWO YEARS OF A HOSPITAL-WIDE FULLY INTEGRATED BIOSIMILARS UTILIZATION MANAGEMENT SYSTEM: AN EFFICIENCY ANALYSIS

2019; Elsevier BV; Volume: 22; Linguagem: Inglês

10.1016/j.jval.2019.09.1697

ISSN

1524-4733

Autores

José Feio, S. Poitier, F Machado, Ana Laura Galhardo Figueira, Eduardo Rabadão, Manuel Brito, J. Fortuna, L. Lemos, Paulo Dinis, C. Viana, Ana Martins, Pedro Pina, N. Vilaça, S. Silva, B. Vandewalle, V. Andreozzi, J Félix,

Tópico(s)

Pharmaceutical studies and practices

Resumo

The fully integrated biosimilars utilization management system (FIBS) at Centro Hospitalar e Universitário de Coimbra (CHUC) relies on prescription and dispensing of biologic therapies by international non-proprietary name and aims to promote the initiation of or switching to (for patients at least 12 months on the same biologic therapy brand) the biologic therapy brand with the best economic value. In the 4th quarter of 2017, FIBS was implemented for etanercept, infliximab and rituximab, and reached remarkable levels of system efficiency of over 85%, less than 12 months after initial FIBS implementation. This research provides an updated efficiency analysis of FIBS, which has entered its second year of implementation and has since included trastuzumab (November, 2018) and adalimumab (December, 2018). System efficiency is defined as the ratio between the observed level of biosimilars utilization and the simulated ideal biosimilars utilization level under FIBS criteria. The step-by-step process and interdependencies between stakeholders under FIBS were implemented in Anylogic, to simulate a counterfactual ideal level of biosimilars utilization over time for all patients on infliximab, etanercept, rituximab, trastuzumab and adalimumab at CHUC between October, 2017 and May, 2019 (cut-off date). A total of 1010 requests for biologic therapy (infliximab: 183; etanercept: 113; rituximab: 399; trastuzumab: 149; adalimumab: 166) were identified for analysis, corresponding to 994 individual patients (mean age: 52.7; female: 59.0%; haematology: 28.1%; gastroenterology: 24.7%; rheumatology: 17.8%; neurology: 9.2%). After 1.5 years of FIBS implementation, system efficiency has further grown up to 95.0% for infliximab, etanercept and rituximab. For trastuzumab and adalimumab, 6 months after their inclusion in FIBS, system efficiency is already reaching 44.8%. In its second year of implementation, The Fully Integrated Biosimilars utilization management System of CHUC keeps demonstrating high levels of efficiency, integration and control over the utilization of biosimilars at hospital level.

Referência(s)
Altmetric
PlumX